Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Neurophysiological Index in ALS.

Michael Swash1, Mamede de Carvalho

  • 1Royal London Hospital, UK. mswash@btinetnet.com

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
|October 30, 2004
PubMed
Summary

The novel Neurophysiological Index (NI) offers a reproducible and sensitive measure for tracking Amyotrophic Lateral Sclerosis (ALS) progression. This index aids in differentiating disease rates and could streamline clinical trials for new ALS therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of the Upper Motor Neuron in the Generation of Fasciculations in Early Disease Stages of Amyotrophic Lateral Sclerosis.

Neurology·2026
Same author

Enhanced spinal motoneuron excitability as a marker of motor neuron dysfunction in primary lateral sclerosis.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same author

Environmental Personal Exposure Clusters to Investigate Multiple Sclerosis and Amyotrophic Lateral Sclerosis Progression.

Studies in health technology and informatics·2026
Same author

Interleukin-6 in ALS: metabolic mediator or marker of ventilatory decline?

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same author

The Cat is Out of the Bag: Confronting False-Positive Risks in Amyotrophic Lateral Sclerosis Clinical Trials.

Neurology·2026
Same author

Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis.

Nature genetics·2026

Area of Science:

  • Neurophysiology
  • Clinical Neurophysiology
  • Neurology

Background:

  • The Neurophysiological Index (NI) is a mathematical derivation of three standard neurophysiological measurements.
  • These measurements, including Compound Muscle Action Potential (CMAP) amplitude, Distal Motor Latency (DML), and F-wave frequency, are routinely performed in clinical neurophysiology labs.
  • The NI integrates aspects of denervation, reinnervation, motor axon degeneration, and anterior horn cell excitability.

Purpose of the Study:

  • To introduce and validate the Neurophysiological Index (NI) as a sensitive measure for assessing disease progression in Amyotrophic Lateral Sclerosis (ALS).
  • To evaluate the NI's reproducibility and its ability to differentiate between rapidly and slowly progressive ALS.
  • To propose the NI's utility in simplifying clinical trial designs for ALS therapies.

Related Experiment Videos

Main Methods:

  • The NI is calculated using a formula: (CMAP amplitude / DML) x F-wave frequency %.
  • The study assessed the intra-rater reliability of the NI in normal subjects and ALS patients.
  • The NI's sensitivity to change and its performance compared to existing measures like the ALSFRS were evaluated.

Main Results:

  • The NI demonstrated good reproducibility in consecutive studies for both normal subjects and ALS patients.
  • The NI proved sensitive to changes over time.
  • In ALS patients, the NI effectively differentiated between rapidly and slowly progressive disease, performing comparably to the ALSFRS.

Conclusions:

  • The Neurophysiological Index (NI) is a simple, reproducible, and sensitive measure for clinical neurophysiology laboratories.
  • The NI can effectively track disease progression in ALS and differentiate disease rates.
  • The NI holds potential for use in clinical trials to assess treatment efficacy, potentially simplifying trial design when combined with clinical benefit measures.